Web Exclusive

“Maintenance therapy is an important part of a cancer treatment regimen for patients who have responded positively to a primary treatment,” said Richard Pazdur, MD, Acting Director of the FDA’s Center for Drug Evaluation and Research and Director of the FDA’s Oncology Center of Excellence. “Zejula offers patients a new treatment option that may help delay the future growth of these cancers, regardless of whether they have a specific genetic mutation,”
The FDA approved ribociclib, in combination with an aromatase inhibitor, for the treatment of postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer.
The influence of genetics on the risk for type 2 diabetes has been suggested by previous research, but new research from the NIH has now outlined in unprecedented detail the role of common genetic variants in the risk for this disease. “Our study has taken us to the most complete understanding yet of the genetic architecture of type 2 diabetes,” said Michael Boehnke, PhD.
While testifying before the Senate Committee on Finance on July 13, 2016, Acting Administrator for CMS Andrew Slavitt said that the agency would consider delaying the implementation of MACRA to address physician and stakeholder concerns. Signed into law in 2015, MACRA will dramatically change the way in which physicians caring for Medicare beneficiaries are paid. The final rule is expected to be released in November of 2016, with an intended start date of January 1, 2017.
Last November, osimertinib (Tagrisso), a third-generation EGFR tyrosine kinase inhibitor (TKI) that targets EGFR mutations, including T790M, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with metastaticEGFR T790M mutation–positive non–small-cell lung cancer (NSCLC) whose disease progressed during or after EGFR TKI therapy.
On May 18, 2016, the US Food and Drug Administration (FDA) approved atezolizumab (Tecentriq; Genentech) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or after platinum-containing chemotherapy, or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Inpatient medical errors are now the third leading cause of death in the United States, ranking behind deaths from heart disease and cancer, according to a new report published in BMJ.
Sarcomas, a group of malignant tumors that develop in soft tissue and bone, can affect any part of the body but most often occur in the abdomen, arms, and legs. Soft-tissue sarcomas typically form in the muscle, cartilage, fat, blood vessels, nerves, and other connective or supportive tissues, including the tendons and joint linings.
In the United States, an estimated 30 million individuals have an eating disorder. Associated with the highest mortality rate of all mental illnesses, eating disorders claim the lives of nearly 20% of those affected.
A critical part of care planning for patients with cancer is the prevention and management of chemotherapy-induced nausea and vomiting (CINV), one of the most feared side effects of chemotherapy.
Page 1 of 6
Results 1 - 10 of 55
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • National Association of Specialty Pharmacy
  • Lynx CME